The adverse events of CDK4/6 inhibitors for HR+/ HER2- breast cancer: an umbrella review of meta-analyses of randomized controlled trials

The adverse events of CDK4/6 inhibitors for HR+/ HER2- breast cancer: an umbrella review of meta-analyses of randomized controlled trials

Background: The clinical selection of three CDK4/6 inhibitors presents a challenging issue, owing to the absence of distinct clinical case characteristics, biomarkers, and their comparable clinical benefits in progression-free survival and overall survival To inform clinical treatment decisions, we...

Full description

Bibliographic Details
Main Authors: Dongqing Pu, Yue Wu, Debo Xu, Guangxi Shi, Hanhan Chen, Dandan Feng, Mengdi Zhang, Jingwei Li
Format: Article
Language:English
Published: Frontiers Media S.A. 2024-01-01
Series:Frontiers in Pharmacology
Subjects:
CDK4/6 inhibitor
adverse event
umbrella review
randomized controlled trial
endocrine therapy
HR+/ HER2-breast cancer
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2024.1269922/full

Internet

https://www.frontiersin.org/articles/10.3389/fphar.2024.1269922/full

Similar Items